Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis
Background: Brodalumab is a monoclonal antibody directed to the IL-17 receptor A, approved for the treatment of moderate-to-severe psoriasis. In phase III clinical trials, brodalumab showed clinical efficacy and a favourable safety profile. However, real-world data on brodalumab treatment are still...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2025-03-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/real-world-experience-with-brodalumab-in-a-portuguese-cohort-of-patients-with-moderate-to-severe-psoriasis/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|